[Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study]

H Jiang, L T Zhi, M Hou, J X Wang, D P Wu, X J Huang, H Jiang, L T Zhi, M Hou, J X Wang, D P Wu, X J Huang

Abstract

Objective: To evaluate the efficacy and safety of generic imatinib (Genike, Chiatai Tianqing Pharmaceutical Group Co., Ltd.) and imatinib (Glevic, Novartis, Switzerland) in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) . Methods: A retrospective study of 323 CML-CP patients (205 in Glivec treatment group and 118 in Genike group) who were ≥ 18 years old receiving imatinib monotherapy over the period of June 2013 to March 2016 was done to compare the differences of cytogenetics, molecular curative effect, survival, and adverse reactions between the two groups. The beginning dosage of imatinib was 400mg per day. There was no statistically difference between the two groups of patients on baseline. Results: ①The median duration of imatinib treatment was 13 (0.5-36) months in Glevic group and 11 (1-31) months in Genike group. ②The rate of complete hematological remission (CHR) had no statistically difference between Glivec and Genike treatment groups[98% (201/205) vs 97.5% (115/118) , χ(2)=0.123, P=0.725]. ③Cumulative rates of major cytogenetic responses (MCyR) at 3, 6 and 12 months after imatinib treatment in Gleevec and Genike groups were (59.7±3.5) % vs (79.8±3.1) %, (89.2±2.6) % vs (59.1±4.7) %, (80.3±4.1) % vs (87.1±4.3) %, respectively, the difference was not statistically significant (χ(2)=0.084, P=0.772) . Cumulative rates of complete cytogenetic response (CCyR) at 3, 6 and 12 months after imatinib treatment in Gleevec and Genike groups were (32.9±3.4) % vs (58.3±3.7) %, (87.4±3.0) % vs (35.2±4.5) %, (64.8±4.8) % vs (87.3±4.7) %, respectively, the difference was not statistically significant (χ(2)=0.660, P=0.417) . ④Cumulative rates of major molecular responses at 6, 12 months after imatinib treatment in Glevic and Genike groups were (24.9±3.3) % vs (57.0±4.1) %, (16.3±4.0) % vs (55.3±7.7) %, respectively, there was no statistical significance (χ(2)=1.617, P=0.204) . Cumulative rates of molecular response 4.5 (MR4.5) at 12 months after imatinib treatment in Glevic and Genike groups were (14.9±3.2) % vs (8.1±2.1) % (χ(2)=3.628, P=0.057) , respectively. ⑤At a median follow-up of 12 months, the difference of progression-free survival (PFS) in Glevic and Genike groups had no statistical significance[ (96.6±1.4) % vs (93.3±2.5) %, χ(2)=2.293, P=0.130]. The difference of event-free survival (EFS) had no statistical significance, either[ (95.6±1.5) % vs (93.3±2.4) %, χ(2)=2.124, P=0.145]. ⑥Genike was well tolerated in patients with CML-CP and had no statistically significant difference in adverse events compared with Glevic group. Conclusion: There were no statistically significant differences in efficacy and safety between Glevic and Genike treatment in newly diagnosed patients with CML-CP.

Keywords: Biosimilar pharmaceuticals; Drug toxicity; Imatinib; Leukemia, myeloid, chronic; Treatment outcome.

Figures

图1. 格列卫与格尼可治疗慢性期慢性髓性白血病患者的累积细胞遗传学反应
图1. 格列卫与格尼可治疗慢性期慢性髓性白血病患者的累积细胞遗传学反应
A：主要细胞遗传学反应；B：完全细胞遗传学反应
图2. 格列卫与格尼可治疗慢性期慢性髓性白血病患者的累积分子学疗效比较
图2. 格列卫与格尼可治疗慢性期慢性髓性白血病患者的累积分子学疗效比较
A：主要分子学反应；B：分子学反应MR4.5
图3. 中位随访12个月时格列卫、格尼可组无进展生存率（A）和无事件生存率（B）比较
图3. 中位随访12个月时格列卫、格尼可组无进展生存率（A）和无事件生存率（B）比较

References

    1. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571(IRIS) 8-year follow up: sustained and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib[J] Blood. 2009;114(22):1126.
    1. Wang AH, Wang YY, Yao Y, et al. Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006[J] J Exp Clin Cancer Res. 2010;29:20. doi: 10.1186/1756-9966-29-20.
    1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J] Blood. 2013;122(6):872–884. doi: 10.1182/blood-2013-05-501569.
    1. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment[J] N Engl J Med. 2003;349(15):1451–1464. doi: 10.1056/NEJMra020777.
    1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia[J] Blood. 2005;105(7):2640–2653. doi: 10.1182/blood-2004-08-3097.
    1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J] Leukemia. 2009;23(6):1054–1061. doi: 10.1038/leu.2009.38.
    1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[J] N Engl J Med. 2006;355(23):2408–2417. doi: 10.1056/NEJMoa062867.
    1. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib[J] Blood. 2014;123(9):1353–1360. doi: 10.1182/blood-2013-06-510396.
    1. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)[J] Blood. 2014;123(4):494–500. doi: 10.1182/blood-2013-06-511592.
    1. Cortes J, Saglio G, Baccarani M, et al. Final study results of the phase 3 Dasatinib versus Imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056)[J] Blood. 2014;124(21):152.
    1. Jiang H, Chen SS, Jiang B, et al. Seven-year response to Imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phase[J] Ann Hematol. 2011;90(1):41–46. doi: 10.1007/s00277-010-1031-0.
    1. 周 励, 王 建祥, 黄 晓军, et al. 达沙替尼与伊马替尼治疗初发慢性髓性白血病的疗效及安全性初步比较[J] 中华血液学杂志. 2013;34(2):93–97. doi: 10.3760/cma.j.issn.0253-2727.2013.02.002.
    1. 王 国蓉, 赵 耀中, 钱 林生, et al. 伊马替尼治疗95例慢性粒细胞白血病的远期疗效及其影响因素分析[J] 中华血液学杂志. 2008;29(1):18–22. doi: 10.3321/j.issn:0253-2727.2008.01.005.
    1. Kim DD, Hamad N, Lee HG, et al. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase[J] Am J Hematol. 2014;89(6):626–632. doi: 10.1002/ajh.23707.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner